Skip to main content

Table 3 Cox proportional hazards 10-year overall survival models

From: Immune profiles and DNA methylation alterations related with non-muscle-invasive bladder cancer outcomes

 

n (%) deceased

n (%) alive

Survival months

Multivariable model

Mean#

HR (95% CI)

P value

Age

180 (29.9)

423 (70.1)

104.3

1.07 (1.04–1.08)

8.7E−9

Sex

     

Male

156 (34.1)

301 (65.9)

102.2

Referent group

 

Female

24 (16.4)

122 (83.6)

111.1

0.62 (0.40–0.96)

0.032

Tumor grade

     

1 + 2

118 (26.1)

334 (73.9)

106.6

Referent group

 

3 + 4

62 (41.1)

89 (58.9)

97.7

1.54 (1.12–2.12)

8.0E−3

Smoking status

     

Non-smoker

19 (18.4)

84 (81.6)

110.8

Referent group

 

Ever-smoker

161 (32.2)

339 (67.8)

103.0

1.66 (1.03–2.67)

0.039

BCG treatment

     

No

152 (29.6)

362 (70.4)

104.8

Referent group

 

Yes

28 (31.5)

61 (68.5)

101.9

1.04 (0.68–1.60)

0.842

mdNLR*

180 (29.9)

423 (70.1)

104.3

1.46 (1.32–1.60)

6.0E−15

  1. HR: hazard ratio, CI: confidence interval, mdNLR: methylation-derived neutrophil to lymphocyte ratio
  2. *Winsorization was used on the top 2% values for fitting linearity assumption
  3. All covariates modeled met proportionality assumptions #: the median survival month for each variable is 120